{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T18:28:11Z","timestamp":1783362491954,"version":"3.54.6"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Folate receptor alpha (FR\u03b1, FOLR1) is the required biomarker for mirvetuximab soravtansine, a treatment option for patients with platinum-resistant ovarian cancer. Since its approval, the drug has been introduced into national drug programs, but prevalence data from the Polish population are lacking. This study provides the first multicenter assessment of FOLR1 expression in Polish ovarian cancer in the context of treatment eligibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed two institutional cohorts comprising 229 epithelial ovarian cancer cases from the Oncology Center in Bydgoszcz and the National Institute of Oncology in Warsaw. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue using the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay on the BenchMark ULTRA platform. Membranous staining of moderate or strong intensity in\u2009\u2265\u200975% of viable tumor cells was considered positive, in accordance with criteria for FOLR1-targeted therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Positive FOLR1 expression was observed in 116 of 229 (50.7%, 95% CI 44.2\u201357.2) analyzed tumors, with 40% showing high expression. In most of these cases, staining intensity was moderate to strong, meeting the established threshold for therapeutic eligibility. In\u2009~\u200918% of tumors, FOLR1 expression fell into the borderline range (65\u201385%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Approximately half of the ovarian cancer patients in this multicenter Polish cohort demonstrated FOLR1 positivity. Although this prevalence is lower than that reported in high-grade serous carcinoma cohorts, it likely reflects histological heterogeneity and methodological differences between studies. These findings provide the first population-based evidence from Poland and support the implementation of FOLR1 testing to guide access to mirvetuximab soravtansine. Further research integrating clinical and molecular data is warranted to validate these results and assess implications for cost-effectiveness and patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12094-025-04179-3","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T11:43:24Z","timestamp":1766403804000},"page":"2143-2149","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Folate receptor alpha in platinum-resistant ovarian cancer: prevalence in a multicenter Polish cohort and review of the evidence"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9873-3285","authenticated-orcid":false,"given":"J\u0119drzej","family":"Borowczak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Dur\u015blewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Durzy\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Cheli\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Filipek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Zdrenka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Szylberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"4179_CR1","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1017\/CBO9780511525391.007","volume-title":"Vitamin receptors","author":"S Weitman","year":"1994","unstructured":"Weitman S, Anderson RGW, Kamen BA. Folate binding proteins. In: Dakshinamurti K, editor. Vitamin receptors. Cambridge: Cambridge University Press; 1994. p. 106\u201336."},{"key":"4179_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1006\/mgme.2000.3027","volume":"71","author":"M Lucock","year":"2000","unstructured":"Lucock M. Folic acid: nutritional biochemistry, molecular biology, and role in disease processes. Mol Genet Metab. 2000;71:121\u201338.","journal-title":"Mol Genet Metab"},{"key":"4179_CR3","doi-asserted-by":"publisher","first-page":"506","DOI":"10.2741\/1815","volume":"11","author":"H Elnakat","year":"2006","unstructured":"Elnakat H, Ratnam M. Role of folate receptor genes in reproduction and related cancers. Front Biosci. 2006;11:506\u201319.","journal-title":"Front Biosci"},{"key":"4179_CR4","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.clinbiochem.2013.03.010","volume":"46","author":"F Leung","year":"2013","unstructured":"Leung F, Dimitromanolakis A, Kobayashi H, Diamandis EP, Kulasingam V. Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients. Clin Biochem. 2013;46:1462\u20138.","journal-title":"Clin Biochem"},{"key":"4179_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1515\/pteridines-2020-0006","volume":"31","author":"Y Wang","year":"2020","unstructured":"Wang Y, Li X, Qu P. Bioinformatics analysis of FOLR1 expression, functional enrichment, related signaling pathways and relationship with prognosis in ovarian cancer. Pteridines. 2020;31:46\u201354.","journal-title":"Pteridines"},{"key":"4179_CR6","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore KN, Angelergues A, Konecny GE, Garc\u00eda Y, Banerjee S, Lorusso D, et al. Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer. N Engl J Med. 2023;389:2162\u201374.","journal-title":"N Engl J Med"},{"key":"4179_CR7","doi-asserted-by":"publisher","first-page":"TPS5622","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS5622","volume":"41","author":"DM O\u2019Malley","year":"2023","unstructured":"O\u2019Malley DM, Myers TKN, Zamagni C, Diver E, Lorusso D. Gloriosa: a randomized, open-label, phase 3 study of mirvetuximab soravtansine with bevacizumab vs. bevacizumab as maintenance in platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. J Clin Oncol. 2023;41:TPS5622.","journal-title":"J Clin Oncol"},{"key":"4179_CR8","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1038\/bjc.2014.567","volume":"111","author":"M K\u00f6bel","year":"2014","unstructured":"K\u00f6bel M, Madore J, Ramus SJ, Clarke BA, Pharoah PDP, Deen S, et al. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. Br J Cancer. 2014;111:2297\u2013307.","journal-title":"Br J Cancer"},{"key":"4179_CR9","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ygyno.2007.11.020","volume":"108","author":"KR Kalli","year":"2008","unstructured":"Kalli KR, Oberg AL, Keeney GL, Christianson TJH, Low PS, Knutson KL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 2008;108:619\u201326.","journal-title":"Gynecol Oncol"},{"key":"4179_CR10","unstructured":"Tucson, U.R.T. VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, Instructions for Use\/Package Insert."},{"key":"4179_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ygyno.2024.09.021","volume":"191","author":"T Rushton","year":"2024","unstructured":"Rushton T, Krause HB, Samec T, Elliott A, Karnezis AN, Toboni MD, et al. Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma. Gynecol Oncol. 2024;191:80\u20135.","journal-title":"Gynecol Oncol"},{"key":"4179_CR12","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.7150\/ijbs.63181","volume":"17","author":"Z Liang","year":"2021","unstructured":"Liang Z, Dong J, Yang N, Li S-D, Yang Z-Y, Huang R, et al. Tandem CAR-T cells targeting FOLR1 and MSLN enhance the antitumor effects in ovarian cancer. Int J Biol Sci. 2021;17:4365\u201376.","journal-title":"Int J Biol Sci"},{"key":"4179_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ygyno.2024.11.010","volume":"192","author":"RA Previs","year":"2025","unstructured":"Previs RA, Strickland KC, Wallen Z, Ko H, Green M, Cooper M, et al. Analysis of real world fr\u03b1 testing in ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol. 2025;192:102\u201310.","journal-title":"Gynecol Oncol"},{"key":"4179_CR14","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ygyno.2017.08.015","volume":"147","author":"LP Martin","year":"2017","unstructured":"Martin LP, Konner JA, Moore KN, Seward SM, Matulonis UA, Perez RP, et al. Characterization of folate receptor alpha (FR\u03b1) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of the FR\u03b1-targeting antibody\u2013drug conjugate mirvetuximab soravtansine. Gynecol Oncol. 2017;147:402\u20137.","journal-title":"Gynecol Oncol"},{"key":"4179_CR15","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41416-022-02031-x","volume":"128","author":"HJ Bax","year":"2023","unstructured":"Bax HJ, Chauhan J, Stavraka C, Santaolalla A, Osborn G, Khiabany A, et al. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes. Br J Cancer. 2023;128:342\u201353.","journal-title":"Br J Cancer"},{"key":"4179_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13048-017-0355-y","volume":"10","author":"SK Srivastava","year":"2017","unstructured":"Srivastava SK, Ahmad A, Miree O, Patel GK, Singh S, Rocconi RP, et al. Racial health disparities in ovarian cancer: not just black and white. J Ovarian Res. 2017;10:58.","journal-title":"J Ovarian Res"},{"key":"4179_CR17","doi-asserted-by":"publisher","first-page":"e251292","DOI":"10.1001\/jamanetworkopen.2025.1292","volume":"8","author":"AJB Smith","year":"2025","unstructured":"Smith AJB, Gleason E, Kadiyala S, Wang X, Howell EA, McCarthy AM. Cancer antigen 125 levels at time of ovarian cancer diagnosis by race and ethnicity. JAMA Netw Open. 2025;8:e251292.","journal-title":"JAMA Netw Open"},{"key":"4179_CR18","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/PAI.0000000000000476","volume":"26","author":"LA Rubinsak","year":"2018","unstructured":"Rubinsak LA, Cohen C, Khanna N, Horowitz IR, Hanley KZ. Folate receptor alpha expression in platinum resistant\/refractory ovarian carcinomas and primary endocervical adenocarcinomas. Appl Immunohistochem Mol Morphol. 2018;26:567\u201372.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"4179_CR19","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ygyno.2013.03.024","volume":"130","author":"E Despierre","year":"2013","unstructured":"Despierre E, Lambrechts S, Leunen K, Berteloot P, Neven P, Amant F, et al. Folate receptor alpha (FRA) expression remains unchanged in epithelial ovarian and endometrial cancer after chemotherapy. Gynecol Oncol. 2013;130:192\u20139.","journal-title":"Gynecol Oncol"},{"key":"4179_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13048-018-0387-y","volume":"11","author":"M-J Huang","year":"2018","unstructured":"Huang M-J, Zhang W, Wang Q, Yang Z-J, Liao S-B, Li L. FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells. J Ovarian Res. 2018;11:15.","journal-title":"J Ovarian Res"},{"key":"4179_CR21","first-page":"1438628","volume":"2019","author":"J Chen","year":"2019","unstructured":"Chen J, Li L. Aberrant expression of folate metabolism enzymes and its diagnosis and survival prediction in ovarian carcinoma. Anal Cell Pathol (Amst). 2019;2019:1438628.","journal-title":"Anal Cell Pathol (Amst)"},{"key":"4179_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.tem.2021.12.003","volume":"33","author":"FZ Nawaz","year":"2022","unstructured":"Nawaz FZ, Kipreos ET. Emerging roles for folate receptor FOLR1 in signaling and cancer. Trends Endocrinol Metab. 2022;33:159\u201374.","journal-title":"Trends Endocrinol Metab"},{"key":"4179_CR23","doi-asserted-by":"publisher","first-page":"153303382211417","DOI":"10.1177\/15330338221141795","volume":"21","author":"C-I Chen","year":"2022","unstructured":"Chen C-I, Li W-S, Chen H-P, Liu K-W, Tsai C-J, Hung W-J, et al. High expression of folate receptor alpha (FOLR1) is associated with aggressive tumor behavior, poor response to chemoradiotherapy, and worse survival in rectal cancer. Technol Cancer Res Treat. 2022;21:15330338221141796.","journal-title":"Technol Cancer Res Treat"},{"key":"4179_CR24","doi-asserted-by":"publisher","first-page":"e70508","DOI":"10.1111\/jcmm.70508","volume":"29","author":"E Jafarzadeh","year":"2025","unstructured":"Jafarzadeh E, Montazeri V, Aliebrahimi S, Sezavar AH, Ghahremani MH, Ostad SN. Targeting cancer stem cells and hedgehog pathway: enhancing cisplatin efficacy in ovarian cancer with metformin. J Cell Mol Med. 2025;29:e70508.","journal-title":"J Cell Mol Med"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04179-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04179-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04179-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:32:21Z","timestamp":1779204741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04179-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["4179"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04179-3","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare that they are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was waived, as the study was conducted on fully anonymized archival diagnostic material. No interventions or additional procedures were performed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board"}},{"value":"Due to the nature of this study, an Informed Consent Statement was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}